Moderna Stock Jumps

Moderna May Have The Best Shot At A Vaccine For Stomach Flu
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.
Moderna Receives $590M From HHS to Develop Bird Flu Vaccine
The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu. This funding, announced Friday by Moderna,
Bird Flu: US Invests $590 Million to Fast-Track Vaccine Development
The Department of Health and Human Services has granted millions of dollars to Moderna to speed up bird flu vaccine development.
Moderna Is Getting $590 Million From the U.S. to Accelerate a Bird Flu Vaccine
The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.
Moderna gets $590M from US government for bird flu vaccine
Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats. Others, including GSK and Pfizer, are also at work on similar shots.
Moderna Stock Jumps On $590M US Award For Bird Flu Vaccine Development, But Retail Doubts Longevity Under Trump
Shares of Moderna Inc. rose over 5% on Tuesday morning, reaching levels last seen more than a week ago, following news of a $590 million award from the U.S. Health and Human Services Department to accelerate its bird flu vaccine development.
Moderna secures $590M in government funding to develop bird flu vaccine
The U.S. government has awarded Moderna $590 million to help speed up the development of a bird flu vaccine. President Trump ends marathon inauguration day at three inaugural balls José Andrés Says This Is the Best Substitute for Salt Macron announces plan for mobilization of volunteers Real-life “Yellowstone” cowboy went from sleeping in a tent to a building a TV empire New Bears coach Ben Johnson eyeing two former NFL head coaches for his staff in Chicago,
Moderna spikes as Oracle’s Larry Ellison touts AI-driven mRNA vaccines
Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.
Moderna says it’s ‘one step closer’ to a norovirus vaccine as the virus spreads across the U.S.
Stomach bug,” “cruise-ship virus,” “winter vomiting disease”—all are nicknames for norovirus, the top cause of vomiting, ...
Monthly Prescribing Reference8d
Moderna Provides Update on Norovirus Vaccine Candidate
Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial investigating a ...
ABC News4d
Moderna awarded $590M to help accelerate development of mRNA-based bird flu vaccine: HHS
There have been 67 confirmed human bird flu cases in the U.S. since April 2024. Moderna has been awarded approximately $590 million from the federal government to help speed up the development of ...
조선일보13d
Moderna starts clinical trials in South Korea for combo flu and COVID-19 vaccine
Moderna advances combo vaccine for flu and COVID-19 with trials starting in March Pharmaceutical companies gear up to tackle ...
Inc2d
Moderna Gets $590 Million to Develop Bird Flu Vaccine
The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.
Newsweek9d
Moderna Shares Plunge After Predicting Steep 2025 Sales Decline
Moderna's revenue and stock price have steadily declined since global demand for COVID-19 vaccines has dwindled. During 2020 and 2021, the company generated massive revenues, fueled by its ...
The Boston Globe9d
Moderna shares plunge after company cuts vaccine sales outlook
Moderna Inc. shares plunged after the company slashed its sales forecast for this year as it struggles with slow demand for its Covid and RSV vaccines. The Cambridge, Massachusetts-based company ...